January 19, 2017 7:42 PM ET

Biotechnology

Company Overview of Envisia Therapeutics Inc.

Company Overview

Envisia Therapeutics Inc. is engaged in the discovery and development of ocular therapeutics for the critical needs in ophthalmology. The company offers ENV515, a prostaglandin analogue that uses a biodegradable PRINT particle formulation to provide sustained intraocular pressure reduction over months. It also provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic, chemical, or other barriers that limit existing ocular therapies; therapeutics based on biocompatible polymers for the delivery of medicines with extended-release kinetics; and topical therapies for treating ocular diseases. The company was founded in 2013 and is based in Morrisville, North ...

419 Davis Drive

Suite 100

Morrisville, NC 27560

United States

Founded in 2013

Phone:

919-973-1440

Fax:

919-973-1441

Key Executives for Envisia Therapeutics Inc.

Chief Executive Officer and Director
Age: 54
Co-Founder, President and Chief Scientific Officer
Age: 50
Executive Chairman
Chief Financial Officer
Chief Medical Officer
Compensation as of Fiscal Year 2016.

Envisia Therapeutics Inc. Key Developments

Envisia Therapeutics Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 04:30 PM

Envisia Therapeutics Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-10-2017 04:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.

Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After a Single Dose in Patients With Glaucoma

Envisia Therapeutics Inc. released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showing clinically meaningful reduction in intraocular pressure (IOP) for the entire nine-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. The ongoing phase 2 trial is a 12-month safety and efficacy evaluation that enrolled five glaucoma patients at sites within the U.S. The pre-washout baseline for all patients in this cohort, treated with LUMIGAN or XALATAN prior to enrollment, was 19.7 mmHg, with a post-washout baseline of 26.1 mmHg for 8 AM IOP. Single low dose of ENV515 decreased the mean + SD 8 AM IOP by 6.7 ± 3.8 mmHg or 26% over nine months (mean of all 8 AM IOPs over nine months). The mean 8 AM IOP after a single low dose of ENV515 was 19.4 mmHg over the nine-month period. ENV515 was well tolerated and there were no serious adverse events, no changes in corneal endothelial cell counts evaluated by an independent reading center, and no changes in corneal thickness. The most common adverse event was early-onset transient hyperemia, or eye redness, related to the dosing procedure.

Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM

Envisia Therapeutics Inc. Presents at Citi's 11th Annual Biotech Conference - Boston, Sep-08-2016 09:00 AM. Venue: The Mandarin Oriental Hotel, Boston, Massachusetts, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 11, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Envisia Therapeutics Inc., please visit www.envisiatherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.